Creatine and Creatinine Metabolism - Physiological Reviews

July 2000 CREATINE AND CREATININE METABOLISM 1189
and creatine phosphate augment ATP and magnesium-dependent,
Fc�RI-mediated activation of phospholipase C in RBL cell ghosts.
J Immunol 151: 3199–3205, 1993.
197. DRINGEN R, VERLEYSDONK S, HAMPRECHT B, WILLKER W,
LEIBFRITZ D, AND BRAND A. Metabolism of glycine in primary
astroglial cells: synthesis of creatine, serine, and glutathione.
J Neurochem 70: 835–840, 1998.
198. DUFFY TE, HOWSE DC, AND PLUM F. Cerebral energy metabolism
during experimental status epilepticus. J Neurochem 24:
925–934, 1975.
199. DUNCAN CJ. Dystrophin and the integrity of the sarcolemma in
Duchenne muscular dystrophy. Experientia 45: 175–177, 1989.
200. DUNCKER DJ, SCHULZ R, FERRARI R, GARCIA-DORADO D,
GUARNIERI C, HEUSCH G, AND VERDOUW PD. “Myocardial
stunning” remaining questions. Cardiovasc Res 38: 549–558, 1998.
201. DUNN JF, BANNISTER N, KEMP GJ, AND PUBLICOVER SJ. Sodium
is elevated in mdx muscles: ionic interactions in dystrophic
cells. J Neurol Sci 114: 76–80, 1993.
202. DUNN JF, FROSTICK S, BROWN G, AND RADDA GK. Energy
status of cells lacking dystrophin: an in vivo/in vitro study of mdx
mouse skeletal muscle. Biochim Biophys Acta 1096: 115–120,
1991.
203. DUNN JF, TRACEY I, AND RADDA GK. Exercise metabolism in
Duchenne muscular dystrophy: a biochemical and [ 31 P]-nuclear
magnetic resonance study of mdx mice. Proc R Soc Lond B Biol
Sci 251: 201–206, 1993.
204. DUNN SR, GABUZDA GM, SUPERDOCK KR, KOLECKI RS,
SCHAEDLER RW, AND SIMENHOFF ML. Induction of creatininase
activity in chronic renal failure: timing of creatinine degradation
and effect of antibiotics. Am J Kidney Dis 29: 72–77, 1997.
205. DYKENS JA, WISEMAN RW, AND HARDIN CD. Preservation of
phosphagen kinase function during transient hypoxia via enzyme
abundance or resistance to oxidative inactivation. J Comp Physiol
B Biochem Syst Environ Physiol 166: 359–368, 1996.
206. DZEJA PP, ZELEZNIKAR RJ, AND GOLDBERG ND. Adenylate
kinase: kinetic behavior in intact cells indicates it is integral to
multiple cellular processes. Mol Cell Biochem 184: 169–182, 1998.
207. EAGLE GR AND SCOPES RK. Inhibition of muscle phosphorylase
a by natural components of the sarcoplasm. Arch Biochem Biophys
210: 540–548, 1981.
208. EARNEST CP, ALMADA AL, AND MITCHELL TL. High-performance
capillary electrophoresis-pure creatine monohydrate reduces
blood lipids in men and women. Clin Sci 91: 113–118, 1996.
209. EARNEST CP, SNELL PG, RODRIGUEZ R, ALMADA AL, AND
MITCHELL TL. The effect of creatine monohydrate ingestion on
anaerobic power indices, muscular strength and body composition.
Acta Physiol Scand 153: 207–209, 1995.
210. EBADI M, SRINIVASAN SK, AND BAXI MD. Oxidative stress and
antioxidant therapy in Parkinson’s disease. Prog Neurobiol 48:
1–19, 1996.
211. EDWARDS RHT. Energy metabolism in normal and dystrophic
human muscle. In: Pathogenesis of Human Muscular Dystrophies,
edited by L. P. Rowland. Amsterdam: Excerpta Medica,
1977, p. 415–429.
212. EDWARDS RJ, MURRAY BP, MURRAY S, SCHULZ T, NEUBERT
D, GANT TW, THORGEIRSSON SS, BOOBIS AR, AND DAVIES DS.
Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic
amines in monkeys and human. Carcinogenesis 15: 829–
836, 1994.
213. EGGLETON P AND EGGLETON GP. The inorganic phosphate and
a labile form of organic phosphate in the gastrocnemius of the
frog. Biochem J 21: 190–195, 1927.
214. EICHLER EE, LU F, SHEN Y, ANTONACCI R, JURECIC V, DOG-
GETT NA, MOYZIS RK, BALDINI A, GIBBS RA, AND NELSON DL.
Duplication of a gene-rich cluster between 16p11.1 and Xq28: a
novel pericentromeric-directed mechanism for paralogous genome
evolution. Hum Mol Genet 5: 899–912, 1996.
215. EISENBRAND G AND TANG W. Food-borne heterocyclic amines.
Chemistry, formation, occurrence and biological activities. A literature
review. Toxicology 84: 1–82, 1993.
216. ELEFF SM, BARKER PB, BLACKBAND SJ, CHATHAM JC, LUTZ
NW, JOHNS DR, BRYAN RN, AND HURKO O. Phosphorus magnetic
resonance spectroscopy of patients with mitochondrial cy-
topathies demonstrates decreased levels of brain phosphocreatine.
Ann Neurol 27: 626–630, 1990.
217. ELGEBALY SA, ALLAM ME, HOUSER S, HASHMI F, FOROUHAR
F, AND MIANO D. Cyclocreatine inhibits neutrophil accumulation
in the myocardium of a canine model of coronary artery occlusion
and reperfusion. J Pharmacol Exp Ther 266: 1670–1677, 1993.
218. ELGEBALY SA, ALLAM ME, ROSSOMANDO F, CORDIS GA, FO-
ROUHAR F, FARGHALY A, AND KREUTZER DL. Cyclocreatine
inhibits the production of neutrophil chemotactic factors from
isolated hearts. Am J Pathol 137: 1233–1241, 1990.
219. ELGEBALY SA, WEI Z, TYLES E, ELKERM AF, HOUSER SL,
GILLIES C, AND KADDURAH-DAOUK R. Enhancement of the
recovery of rat hearts after prolonged cold storage by cyclocreatine
phosphate. Transplantation 57: 803–806, 1994.
220. ELLINGTON WR. Arginine kinase and creatine kinase appear to
be present in the same cells of an echinoderm muscle. J Exp Biol
158: 591–597, 1991.
221. ELLINGTON WR. Phosphocreatine represents a thermodynamic
and functional improvement over other muscle phosphagens. J
Exp Biol 143: 177–194, 1989.
222. EMERY AEH. Duchenne muscular dystrophy. Genetic aspects,
carrier detection and antenatal diagnosis. Br Med Bull 36: 117–
122, 1980.
223. ENDO H AND TAKAHASHI K. Identification and property of the
mutagenic principle formed from a food-component, methylguanidine,
after nitrosation in simulated gastric juice. Biochem Biophys
Res Commun 54: 1384–1392, 1973.
224. ENDO H, TAKAHASHI K, AND AOYAGI H. Screening of compounds
structurally and functionally related to N-methyl-N�-nitro-
N-nitrosoguanidine, a gastric carcinogen. Jpn J Cancer Res 65:
45–54, 1974.
225. ENGELHARDT M, NEUMANN G, BERBALK A, AND REUTER I.
Creatine supplementation in endurance sports. Med Sci Sports
Exercise 30: 1123–1129, 1998.
226. ENNOR AH AND MORRISON JF. Biochemistry of the phosphagens
and related guanidines. Physiol Rev 38: 631–674, 1958.
227. ENNOR AH AND ROSENBERG H. The determination and distribution
of phosphocreatine in animal tissues. Biochem J 51: 606–610,
1952.
228. EPPENBERGER-EBERHARDT M, RIESINGER I, MESSERLI M,
SCHWARB P, MÜLLER M, EPPENBERGER HM, AND WALLI-
MANN T. Adult rat cardiomyocytes cultured in creatine-deficient
medium display large mitochondria with paracrystalline inclusions
enriched for creatine kinase. J Cell Biol 113: 289–302, 1991.
229. ESDERS TW AND LYNN SY. Purification and properties of creatinine
iminohydrolase from Flavobacterium filamentosum. J Biol
Chem 260: 3915–3922, 1985.
230. FALLON J, MATTHEWS RT, HYMAN BT, AND BEAL MF. MPP �
produces progressive neuronal degeneration which is mediated
by oxidative stress. Exp Neurol 144: 193–198, 1997.
231. FATTERPAKER P, MARFATIA U, AND SREENIVASAN A. Influence
of folic acid and vitamin B 12 on formation of creatine in vitro
and in vivo. Nature 167: 1067–1068, 1951.
232. FEBBRAIO MA, FLANAGAN TR, SNOW RJ, ZHAO S, AND CAREY
MF. Effect of creatine supplementation on intramuscular TCr,
metabolism and performance during intermittent, supramaximal
exercise in humans. Acta Physiol Scand 155: 387–395, 1995.
233. FEEBACK DL, LOCKLEAR I, AND BRUMBACK RA. Metabolic
myopathy produced by dinitrofluorobenzene inhibition of creatine
phosphokinase. J Neurol Sci 88: 219–228, 1988.
234. FELL V, POLLITT RJ, SAMPSON GA, AND WRIGHT T. Ornithinemia,
hyperammonemia, and homocitrullinuria. A disease associated
with mental retardation and possibly caused by defective
mitochondrial transport. Am J Dis Child 127: 752–756, 1974.
235. FELTON JS AND GENTILE JM. Special issue “Mutagenic/carcinogenic
N-substituted aryl compounds.” Mutat Res 376: 1–272, 1997.
236. FELTON JS AND KNIZE MG. Heterocyclic-amine mutagens/carcinogens
in foods. In: Chemical Carcinogenesis and Mutagenesis I,
edited by C. S. Cooper and P. L. Grover. Berlin: Springer, 1990, p.
471–502.
237. FELTON JS AND KNIZE MG. New mutagens from cooked food. In:
Mutagens and Carcinogens in the Diet, edited by M. W. Pariza,